Supinoxin (RX-5902), a small-molecule drug initially developed for triple-negative breast cancer, has demonstrated promising efficacy against small-cell lung cancer (SCLC), a highly aggressive and treatment-resistant form of lung cancer. Researchers at Purdue University have found that Supinoxin inhibits the DDX5 protein, an RNA helicase critical for tumor cell proliferation. By targeting DDX5, Supinoxin effectively suppresses tumor growth in SCLC cell lines and animal models. The drug’s mechanism involves disrupting mitochondrial activity, leading to reduced energy production essential for cancer cell survival. This approach offers a potential therapeutic avenue for SCLC patients, who currently have limited treatment options and poor survival rates.
The researchers suggest that combining Supinoxin with other therapies could enhance its effectiveness in treating SCLC. While Supinoxin alone may not eradicate tumors, it appears to suppress their growth sufficiently to make them more susceptible to additional treatments. This strategy aligns with the growing trend of combination therapies in oncology, aiming to tackle cancer from multiple angles to overcome resistance mechanisms. Given its established safety profile from previous clinical trials in breast cancer, Supinoxin presents a compelling candidate for repurposing in SCLC treatment. Click for More Details
